Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

USA - NASDAQ:XFOR - US98420X2027 - Common Stock

3.57 USD
+0.12 (+3.48%)
Last: 9/24/2025, 8:00:02 PM
3.51 USD
-0.06 (-1.68%)
After Hours: 9/24/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, XFOR scores 2 out of 10 in our fundamental rating. XFOR was compared to 538 industry peers in the Biotechnology industry. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative. XFOR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XFOR has reported negative net income.
In the past year XFOR has reported a negative cash flow from operations.
In the past 5 years XFOR always reported negative net income.
XFOR had a negative operating cash flow in each of the past 5 years.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -96.96%, XFOR is not doing good in the industry: 75.46% of the companies in the same industry are doing better.
XFOR has a worse Return On Equity (-2568.02%) than 83.09% of its industry peers.
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

Looking at the Gross Margin, with a value of 83.00%, XFOR belongs to the top of the industry, outperforming 86.25% of the companies in the same industry.
XFOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XFOR has more shares outstanding
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
The debt/assets ratio for XFOR is higher compared to a year ago.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that XFOR is in the distress zone and has some risk of bankruptcy.
XFOR has a worse Altman-Z score (-9.40) than 71.56% of its industry peers.
XFOR has a Debt/Equity ratio of 19.10. This is a high value indicating a heavy dependency on external financing.
XFOR has a worse Debt to Equity ratio (19.10) than 83.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACC11.86%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

XFOR has a Current Ratio of 3.19. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.19, XFOR is not doing good in the industry: 62.27% of the companies in the same industry are doing better.
A Quick Ratio of 3.05 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a Quick ratio of 3.05. This is in the lower half of the industry: XFOR underperforms 60.59% of its industry peers.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.05
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for XFOR have decreased strongly by -12.35% in the last year.
XFOR shows a strong growth in Revenue. In the last year, the Revenue has grown by 5721.31%.
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%

3.2 Future

The Earnings Per Share is expected to grow by 14.51% on average over the next years. This is quite good.
The Revenue is expected to grow by 127.57% on average over the next years. This is a very strong growth
EPS Next Y76.99%
EPS Next 2Y36.44%
EPS Next 3Y23.99%
EPS Next 5Y14.51%
Revenue Next Year1511.73%
Revenue Next 2Y206.53%
Revenue Next 3Y267.06%
Revenue Next 5Y127.57%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 23.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.44%
EPS Next 3Y23.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XFOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (9/24/2025, 8:00:02 PM)

After market: 3.51 -0.06 (-1.68%)

3.57

+0.12 (+3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners52.93%
Inst Owner Change-96.85%
Ins Owners2.6%
Ins Owner Change9.91%
Market Cap40.73M
Analysts83.64
Price Target8.87 (148.46%)
Short Float %14.93%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.23%
Min EPS beat(2)21.58%
Max EPS beat(2)100.88%
EPS beat(4)2
Avg EPS beat(4)27.08%
Min EPS beat(4)-12.04%
Max EPS beat(4)100.88%
EPS beat(8)4
Avg EPS beat(8)-140.1%
EPS beat(12)6
Avg EPS beat(12)-99.51%
EPS beat(16)7
Avg EPS beat(16)-77.16%
Revenue beat(2)2
Avg Revenue beat(2)666.75%
Min Revenue beat(2)20.01%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)325.24%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-75.97%
PT rev (3m)-79.61%
EPS NQ rev (1m)64.11%
EPS NQ rev (3m)72.85%
EPS NY rev (1m)0%
EPS NY rev (3m)75.41%
Revenue NQ rev (1m)-3.07%
Revenue NQ rev (3m)-8.52%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)16.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.24
P/FCF N/A
P/OCF N/A
P/B 10.26
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.83
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-9.85
FCFYN/A
OCF(TTM)-9.58
OCFYN/A
SpS2.87
BVpS0.35
TBVpS-2.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.52%
Cap/Sales 9.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.05
Altman-Z -9.4
F-Score1
WACC11.86%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
EPS Next Y76.99%
EPS Next 2Y36.44%
EPS Next 3Y23.99%
EPS Next 5Y14.51%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%
Revenue Next Year1511.73%
Revenue Next 2Y206.53%
Revenue Next 3Y267.06%
Revenue Next 5Y127.57%
EBIT growth 1Y14.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.59%
OCF growth 3YN/A
OCF growth 5YN/A